AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29573665 — intervention group
Group type: COMPARATOR
Intervention: sHR+ (ER–/PgR+)
Number of subjects: 571
Study 26967219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF: folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Number of subjects: 24
Study 26967219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF)
Number of subjects: 24
Study 26967219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 24
Study 24639042 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 36
Study 22852832 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Care (multi-component smoking cessation intervention including up to three months of free FDA-approved smoking cessation medication and five proactive computerized telephone calls)
Number of subjects: 0
Study 22852832 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (recommendation for a smoking cessation medication and information about community resources)
Number of subjects: 0
Study 22852832 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Care
Number of subjects: 0
Study 19383060 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glycaemia (including diabetes, impaired fasting glucose, post-stroke dysglycaemia)
Number of subjects: 224
Study 19383060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 224
Study 19383060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 224
Study 19383060 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of abnormal glycaemia, hypertension, and dyslipidaemia
Number of subjects: 224
Study 17274708 — intervention group
Group type: EXPERIMENTAL
Intervention: Test SEI with nanometer-sized calcium phosphate treatment
Number of subjects: 15
Study 17274708 — intervention group
Group type: COMPARATOR
Intervention: Control SEI with dual acid-etched surface without treatment
Number of subjects: 15
Study 15159491 — intervention group
Group type: COMPARATOR
Intervention: Minocycline 200 mg/day for 6 months
Number of subjects: 42
Study 15159491 — intervention group
Group type: COMPARATOR
Intervention: Minocycline up to 400 mg/day for 8 months (mean tolerated dose 387 mg/day)
Number of subjects: 42
Study 12005090 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria chemoprophylaxis during the first year of life
Number of subjects: 675
Study 12005090 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with malaria episodes
Number of subjects: 675
Study 12005090 — intervention group
Group type: COMPARATOR
Intervention: Children without malaria episodes
Number of subjects: 675
Study 9828914 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-GHRH test with hydrocortisone (HC) 80 mg/day for 1 day
Number of subjects: 24
Study 9828914 — intervention group
Group type: COMPARATOR
Intervention: PD-GHRH test with no glucocorticoid pretreatment
Number of subjects: 24
Study 9828914 — intervention group
Group type: COMPARATOR
Intervention: PD-GHRH test with conventional HC therapy (30 mg/day for 1 and 3 days)
Number of subjects: 24
Study 9828914 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-GHRH test with HC (80 mg/day for 1 day)
Number of subjects: 24
Study 9828914 — intervention group
Group type: COMPARATOR
Intervention: PD-GHRH test with short-term hypocortisolism
Number of subjects: 24
Study 8055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Long perimenopausal period (at least 27 months)
Number of subjects: 2565
Study 8055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior depression
Number of subjects: 2565
Study 8055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of natural menopause
Number of subjects: 2565
Study 8055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Long perimenopause
Number of subjects: 2565
Study 2678497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (15 mg)
Number of subjects: 81
Study 2678497 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (0.5 mg)
Number of subjects: 81
Study 1098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered solution (Bamyl‐SR, AB Hässle, Sweden)
Number of subjects: 7
Study 1098134 — intervention group
Group type: COMPARATOR
Intervention: Conventional disintegrating tablet (MagnecylR, ACO, Sweden)
Number of subjects: 7
Study 31901246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (3 grams daily for 8 weeks)
Number of subjects: 44
Study 31901246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 44
Study 31238029 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion strategy to maintain oxygen delivery index (DO2i) greater than 280 mL/min/m2
Number of subjects: 19410
Study 31238029 — intervention group
Group type: COMPARATOR
Intervention: Below the optimal DO2i threshold of 270 mL/min/m2
Number of subjects: 19410
Study 28619302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulas
Number of subjects: 117
Study 28619302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 117
Study 25208904 — intervention group
Group type: EXPERIMENTAL
Intervention: Padma® 28 (Tibetan herbal mixture)
Number of subjects: 80
Study 25208904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23382484 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg sildenafil (PDE5 inhibitor)
Number of subjects: 15
Study 23382484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23382484 — intervention group
Group type: COMPARATOR
Intervention: 25mg hydralazine (control, cGMP-independent vasodilator)
Number of subjects: 15
Study 21281875 — intervention group
Group type: EXPERIMENTAL
Intervention: Active grass pollen immunotherapy (n = 7)
Number of subjects: 13
Study 21281875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study 19457484 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 10
Study 19457484 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol + ethanol
Number of subjects: 10
Study 19457484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 10
Study 19457484 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 16515093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss
Number of subjects: 9
Study 16515093 — intervention group
Group type: COMPARATOR
Intervention: Control (no Bio‐Oss)
Number of subjects: 9
Study 15607396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 24
Study 15607396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11006178 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17 beta‐oestradiol 2 mg and norethisterone acetate 1 mg/day per os
Number of subjects: 120
Study 11006178 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day per os
Number of subjects: 120
Study 11006178 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17 beta‐oestradiol 2 mg, norethisterone acetate 1 mg/day per os and alendronate 10 mg/day per os
Number of subjects: 120
Study 11006178 — intervention group
Group type: COMPARATOR
Intervention: Control group (HRT only)
Number of subjects: 120
Study 11006178 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 120
Study 9276782 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation audiotapes
Number of subjects: 0
Study 9276782 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral audiotapes
Number of subjects: 0
Study 8510897 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fundus on admission
Number of subjects: 56
Study 8510897 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilledema
Number of subjects: 56
Study 8510897 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal edema outside the posterior vascular arcades
Number of subjects: 56
Study 2436414 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 35
Study 2436414 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment
Number of subjects: 35
Study 2436414 — intervention group
Group type: COMPARATOR
Intervention: Untreated hands (control)
Number of subjects: 35
Study 31630870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg
Number of subjects: 278
Study 31630870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg single-dose
Number of subjects: 278
Study 31630870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg 2-dose
Number of subjects: 278
Study 31630870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 30378591 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring during anesthesia
Number of subjects: 81
Study 30378591 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative hemodynamic monitoring (non-BIS group)
Number of subjects: 81
Study 26621218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 400
Study 26621218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (flexible-dose treatment)
Number of subjects: 400
Study 26621218 — intervention group
Group type: COMPARATOR
Intervention: Engagement Interview
Number of subjects: 400
Study 26621218 — intervention group
Group type: COMPARATOR
Intervention: Control visit
Number of subjects: 400
Study 26621218 — intervention group
Group type: COMPARATOR
Intervention: No treatment (longitudinal cohort)
Number of subjects: 400
Study 24430407 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 × 10⁶ allogeneic mesenchymal stem cells
Number of subjects: 55
Study 24430407 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 × 10⁶ allogeneic mesenchymal stem cells
Number of subjects: 55
Study 24430407 — intervention group
Group type: COMPARATOR
Intervention: sodium hyaluronate (control)
Number of subjects: 55
Study 24430407 — intervention group
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Number of subjects: 55
Study 22754044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5‐hr nighttime sleep opportunity
Number of subjects: 18
Study 20357692 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected eating (PAT)
Number of subjects: 143
Study 20357692 — intervention group
Group type: COMPARATOR
Intervention: Lipase directed (LIP)
Number of subjects: 143
Study 18684247 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered atrial pacing (PAC Suppression, Post‐PAC Response, and Post‐Exercise Response)
Number of subjects: 171
Study 18684247 — intervention group
Group type: COMPARATOR
Intervention: Combined group (continuous and triggered atrial pacing with Pace Conditioning)
Number of subjects: 171
Study 18684247 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered group after crossover
Number of subjects: 171
Study 18684247 — intervention group
Group type: COMPARATOR
Intervention: Combined group after crossover
Number of subjects: 171
Study 16105425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation with recruitment maneuvers (RM)
Number of subjects: 28
Study 16105425 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume ventilation without recruitment maneuvers (non-RM group)
Number of subjects: 28
Study 12682804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg orally every 6 h (group A)
Number of subjects: 31
Study 12682804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.1 mg/kg orally every 3 h (group B)
Number of subjects: 31
Study 12682804 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 31
Study 10597336 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 2
Study 10597336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8607306 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group (15 ml of bupivacaine 0.75% via thoracic epidural route)
Number of subjects: 16
Study 8607306 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum group (20‐30 mg of papaveretum i.v.)
Number of subjects: 16
Study 1709600 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug regimen (rifampicin, isoniazid, pyrazinamide or thiacetazone)
Number of subjects: 90
Study 1709600 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug regimen (rifampicin, isoniazid)
Number of subjects: 90
Study 1709600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and isoniazid
Number of subjects: 90
Study 1709600 — intervention group
Group type: COMPARATOR
Intervention: Single-drug therapy with isoniazid
Number of subjects: 90
Study 1709600 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after therapy
Number of subjects: 90
Study 7029975 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative telecobalt irradiation of the minor pelvis (50 to 52 Gy)
Number of subjects: 120
Study 7029975 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery (Wertheim‐Meigs)
Number of subjects: 120
Study 30699054 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette starter pack (a second‐generation refillable e‐cigarette with one bottle of nicotine e‐liquid [18 mg per milliliter])
Number of subjects: 886
Study 30699054 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-replacement products of their choice
Number of subjects: 886
Study 30699054 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette group
Number of subjects: 886
Study 30699054 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-replacement group
Number of subjects: 886
Study 30699054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 886
Study 28143481 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-22 levels
Number of subjects: 504
Study 28143481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk factors
Number of subjects: 504
Study 25534776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus (8×10 colony-forming unit per day) for 6 months
Number of subjects: 20
Study 25534776 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (25 mg · kg · day for 4 days/wk) for 6 months
Number of subjects: 20
Study 25534776 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control, no prophylaxis)
Number of subjects: 20
Study 25534776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus
Number of subjects: 20
Study 24338190 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient cardiac rehabilitation
Number of subjects: 60
Study 24338190 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (Control)
Number of subjects: 60
Study 22027083 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (RBBB)
Number of subjects: 6676
Study 22027083 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch block (LBBB)
Number of subjects: 6676
Study 22027083 — intervention group
Group type: COMPARATOR
Intervention: No bundle branch block (BBB)
Number of subjects: 6676
Study 22027083 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (RBBB) with reduced left ventricular (LV) systolic function
Number of subjects: 6676
Study 22027083 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch block (LBBB) with preserved left ventricular (LV) systolic function
Number of subjects: 6676
Study 19159944 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with recombinant arylsulfatase B (Naglazyme)
Number of subjects: 7
Study 17968979 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 141
Study 17968979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 15308475 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase lysine intake (37.7 mg.kg(‐1).day(‐1))
Number of subjects: 5
Study 15308475 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase lysine intake (35.0 mg.kg(‐1).day(‐1))
Number of subjects: 5
Study 11268025 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal stimulation of nerve segments
Number of subjects: 86
Study 11268025 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal stimulation of nerve segments
Number of subjects: 86
Study 11268025 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal and distal stimulation of nerve segments
Number of subjects: 86
Study 9273984 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, education, or a combination of education and social support
Number of subjects: 363
Study 9273984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363
Study 8197893 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Expectancy Questionnaire Tension Reduction Scale
Number of subjects: 0
Study 3066518 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 65
Study 3066518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 65
Study 2083046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.03% triclosan and 0.25% copolymer of methoxyethylene and maleic acid
Number of subjects: 47
Study 2083046 — intervention group
Group type: COMPARATOR
Intervention: Water placebo mouthrinse
Number of subjects: 47
Study 1093352 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-Valerate steroid aerosol
Number of subjects: 18
Study 1093352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1093352 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-Valerate
Number of subjects: 18
Study 31211805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (3 mg/kg body weight, intravenous)
Number of subjects: 41
Study 31211805 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sterile saline solution (control)
Number of subjects: 41
Study 28026901 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised twice‐weekly resistance exercise training and 150 min/wk of aerobic exercise
Number of subjects: 121
Study 28026901 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study 26342247 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ionophore solution (GM508 Cult‐Active) for 15 minutes after intracytoplasmic sperm injection
Number of subjects: 296
Study 26342247 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium ionophore treatment)
Number of subjects: 296
Study 23433446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel plus S‐1 (TS)
Number of subjects: 240
Study 23433446 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus 5‐fluorouracil/calcium folinate (TLF)
Number of subjects: 240
Study 22340792 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin local injection
Number of subjects: 32
Study 19570601 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program (monthly use for one year)
Number of subjects: 79
Study 19570601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-learning program)
Number of subjects: 79
Study 16757701 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology and HPV testing using Hybrid Capture 2 assay
Number of subjects: 33364
Study 16757701 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing alone at > or = 1 pg/mL
Number of subjects: 33364
Study 16757701 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing alone at > or = 2 pg/mL
Number of subjects: 33364
Study 16757701 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology alone
Number of subjects: 33364
Study 16757701 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 33364
Study 15075657 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall lift (AWL)
Number of subjects: 40
Study 15075657 — intervention group
Group type: COMPARATOR
Intervention: Positive-pressure capnoperitoneum (PPCpn)
Number of subjects: 40
Study 11255519 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance testing and clinical judgment after initial treatment failure (secondary resistance testing)
Number of subjects: 0
Study 11255519 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance testing and clinical judgment before initiation of antiretroviral therapy (primary resistance testing)
Number of subjects: 0
Study 11255519 — intervention group
Group type: COMPARATOR
Intervention: Secondary resistance testing
Number of subjects: 0
Study 11255519 — intervention group
Group type: COMPARATOR
Intervention: Primary resistance testing
Number of subjects: 0
Study 7970014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (24 to 36 mg daily in three doses)
Number of subjects: 187
Study 7970014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 187
Study 7970014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 3118725 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin
Number of subjects: 94
Study 3118725 — intervention group
Group type: COMPARATOR
Intervention: Triple-dose cefoxitin
Number of subjects: 94
Study 31346621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vollure (Juvéderm Vollure XC)
Number of subjects: 123
Study 31346621 — intervention group
Group type: COMPARATOR
Intervention: Control filler
Number of subjects: 123
Study 31102373 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape intervention (digital weight gain prevention intervention)
Number of subjects: 91
Study 28645960 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) group received seven PT sessions (one preoperative and six postoperative) incorporating education, manual therapy, and a progressive rehabilitation programme of home, aquatic, and gym exercises.
Number of subjects: 30
Study 28645960 — intervention group
Group type: COMPARATOR
Intervention: Control group did not undertake PT rehabilitation.
Number of subjects: 30
Study 25254356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon counterpulsation (IABP)
Number of subjects: 149
Study 25254356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 149
Study 23381178 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative localization methods (palpation method and Kirschner wire method)
Number of subjects: 220